Compare · Mitochondrial peptide
Humanin vs MOTS-c
Both are mitochondrial peptide compounds. Here's how they line up on the evidence — graded the same way.
| Humanin | MOTS-c | |
|---|---|---|
| Evidence | Animal only | Animal only |
| Class | Mitochondrial peptide | Mitochondrial peptide |
| Summary | Humanin is a mitochondrial-derived peptide with interesting cell and animal data in aging and neuroprotection, but the human evidence is entirely observational — no interventional trial of administered humanin in people exists. It's unapproved and effectively uncharacterized for safety in humans. | MOTS-c is a mitochondrial peptide with strong rodent metabolic data but no completed, published human efficacy trial. It's unapproved and WADA-banned. |
| Full profile → | Full profile → |
Humanin
Humanin is one of the more scientifically intriguing peptides in the "longevity" corner of the gray market: it's the first mitochondrial-derived peptide ever found, it has a plausible cytoprotective mechanism, and its blood levels fall with age. But as of mid-2026, the human evidence that injecting…
MOTS-c
MOTS-c is one of the most-hyped "exercise in a vial" peptides, and the underlying biology is genuinely interesting. But the human evidence that it does anything useful is, as of mid-2026, essentially absent.